April | 2017 | Cyprotex

Cyprotex becomes one of the founding companies of the Alliance for Human Relevant Science

Cyprotex has become one of the founding companies of a new collaboration entitled the Alliance for Human […]

Traditionally, vanoxerine was developed as a dopamine transporter antagonist for use in the treatment of cocaine addiction, […]

Advances in bone research have allowed the development of inorganic calcium- and phosphate-based bone graft substitutes (BGSs). […]

Traditional phototoxicity testing compares the cytotoxicity of test substances in the presence and absence of ultraviolet A […]

It is reported that approximately 25% of cases of renal failure are related to drug-induced nephrotoxicity. This […]